Scientists at Immanuel Kant Baltic Federal University have taken a step towards more accurate prediction of recovery in patients with metabolic disorders following a stroke. For the first time, researchers have identified immunological markers — and combinations thereof — that could hold the key to personalised treatment. The results of the study are published in the Korsakov Journal of Neurology and Psychiatry.
Stroke is a severe cerebrovascular condition. The presence of metabolic disorders — including hypertension, diabetes, obesity, hypercholesterolaemia, and hyperglycaemia — significantly hinders recovery, yet standard biochemical tests and clinical data offer only a limited understanding of the patient's true status.
| Anastasia Tyntyrova, MD, Neurologist at the IKBFU Centre for Cognitive Health: |
| Metabolic disorders can certainly be diagnosed using standard biochemical blood tests and a physical examination. However, this is merely the tip of the iceberg. Behind these indicators lie more complex neuroimmune processes — processes that can only be assessed using modern laboratory testing methods. Their prognostic value for patient recovery, in turn, can only be determined using artificial intelligence. This study has allowed us to identify specific immune system markers that are closely linked to the course of metabolic disorders and the patient's recovery following a stroke. |
Certain immune system parameters — in particular, macrophage migration inhibitory factor (MIF) and chemokines — CCR1 receptor ligands such as MCP‑1/CCL2 and MIP‑1α/CCL3 — both individually and in combination with key biochemical indicators, can serve as important prognostic markers. To assess their significance, the researchers applied artificial intelligence methods, which help to identify non‑obvious patterns in large datasets. The results may form the basis for the development and algorithmisation of prognostic models for ischaemic stroke outcomes. Furthermore, a detailed study and understanding of the immunopathogenesis of various diseases will expand the possibilities of omics technologies and targeted therapy.
| Anastasia Tyntyrova, MD, Neurologist at the IKBFU Centre for Cognitive Health: |
| Our findings thus form part of large‑scale research on the one hand, and represent a new direction in personalised medicine on the other. |
User profile for student
User profile for student
I give consent to the processing of the personal data provided, with Personal Data Processing Policy acquainted
Confirm consent
